IXHL vs. ATOS, IVA, OGI, ACRV, ZVRA, TELO, LFCR, TRVI, CDT, and GALT
Should you be buying Incannex Healthcare stock or one of its competitors? The main competitors of Incannex Healthcare include Atossa Therapeutics (ATOS), Inventiva (IVA), Organigram (OGI), Acrivon Therapeutics (ACRV), Zevra Therapeutics (ZVRA), Telomir Pharmaceuticals (TELO), Lifecore Biomedical (LFCR), Trevi Therapeutics (TRVI), Conduit Pharmaceuticals (CDT), and Galectin Therapeutics (GALT). These companies are all part of the "pharmaceutical preparations" industry.
Atossa Therapeutics (NASDAQ:ATOS) and Incannex Healthcare (NASDAQ:IXHL) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, valuation, earnings, analyst recommendations, risk, institutional ownership, community ranking, media sentiment and dividends.
In the previous week, Atossa Therapeutics had 23 more articles in the media than Incannex Healthcare. MarketBeat recorded 25 mentions for Atossa Therapeutics and 2 mentions for Incannex Healthcare. Atossa Therapeutics' average media sentiment score of 1.51 beat Incannex Healthcare's score of 0.64 indicating that Incannex Healthcare is being referred to more favorably in the news media.
Atossa Therapeutics received 230 more outperform votes than Incannex Healthcare when rated by MarketBeat users.
12.7% of Atossa Therapeutics shares are owned by institutional investors. Comparatively, 0.4% of Incannex Healthcare shares are owned by institutional investors. 7.8% of Atossa Therapeutics shares are owned by company insiders. Comparatively, 14.6% of Incannex Healthcare shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Atossa Therapeutics has a beta of 1.27, suggesting that its share price is 27% more volatile than the S&P 500. Comparatively, Incannex Healthcare has a beta of 8.65, suggesting that its share price is 765% more volatile than the S&P 500.
Atossa Therapeutics currently has a consensus target price of $5.50, indicating a potential upside of 250.32%. Given Incannex Healthcare's higher possible upside, equities research analysts plainly believe Atossa Therapeutics is more favorable than Incannex Healthcare.
Incannex Healthcare has higher revenue and earnings than Atossa Therapeutics.
Atossa Therapeutics' return on equity of 0.00% beat Incannex Healthcare's return on equity.
Summary
Incannex Healthcare beats Atossa Therapeutics on 7 of the 12 factors compared between the two stocks.
Get Incannex Healthcare News Delivered to You Automatically
Sign up to receive the latest news and ratings for IXHL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IXHL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Incannex Healthcare Competitors List
Related Companies and Tools
